Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice

Fig. 1

Anti-tumor effects of sonidegib, 177Lu-octreotate and combination treatment on GOT1 tumors in nude mice. a mean relative tumor volume versus time for controls and animals treated with sonidegib, 177Lu-octreotate, or a combination of both. b mean tumor volume versus time, until the first animal had to be killed on account of too high tumor burden, in each treatment group and controls. c percentage of animals in each treatment group without tumor progression. Error bars indicate SD. x, †, ‡ and * indicate time points with statistically significant differences between sonidegib and control, 177Lu-octreotate and control, combination and control, and combination and sonidegib treatment groups, respectively (Student’s t-test, p < 0.05). ↓ indicates the time for treatment start

Back to article page